Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJM199309303291415 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fertility induction associated with improved peripheral reproductive parameters in male mice subjected to GH and levothyroxine replacement.
Arch Endocrinol Metab
January 2025
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Laboratório de Hormônios e Genética Molecular LIM/42 Divisão de Endocrinologia São PauloSP Brasil Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Laboratório de Hormônios e Genética Molecular LIM/42 - Divisão de Endocrinologia, São Paulo, SP, Brasil.
Objective: The aim of this study was to characterize the parameters of reproductive anatomy and pituitary hormone expression levels in ames dwarf mice ).
Materials And Methods: Male mice aged 30 days received daily intraperitoneal injections of recombinant human GH and levothyroxine three times weekly for 60 days. The sexual maturation of these animals was compared with that of their wild-type ( ) and untreated ( ) siblings.
Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial.
Ann Rheum Dis
January 2025
Rheumatology Center, Toulouse University Hospital, Toulouse, France.
Objectives: To compare two strategies-a hydrocortisone replacement strategy and a prednisone tapering strategy-for their success in glucocorticoid discontinuation in patients with rheumatoid arthritis (RA) with low disease activity (LDA).
Methods: The Strategies for glucocorticoid TApering in Rheumatoid arthritis (STAR) study was a double- blind, double-placebo randomised controlled trial including patients with RA receiving a stable dose of glucocorticoid 5 mg/day for ≥3 months and were in LDA for ≥3 months. Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before discontinuation or to taper prednisone by 1 mg/day every month until complete discontinuation, contingent on maintaining LDA.
Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.
Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, 1699 SW 16th Ave, Building A, Gainesville, FL, 32608, USA.
Type 1 diabetes mellitus (T1DM) is characterized by the progressive, autoimmune-mediated destruction of β cells. As such, restoring immunoregulation early in the disease course is sought to retain endogenous insulin production. Nevertheless, in the more than 100 years since the discovery of insulin, treatment of T1DM has focused primarily on hormone replacement and glucose monitoring.
View Article and Find Full Text PDFRoxadustat-Induced Central Hypothyroidism Masked by Uremia at the Initiation of Hemodialysis: A Case Report.
Cureus
December 2024
Nephrology, Yokohama Municipal Citizen's Hospital, Yokohama, JPN.
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of orally administered medications for renal anemia in patients with end-stage renal disease (ESRD). Roxadustat, a HIF-PHI, has a structure similar to that of triiodothyronine and may work as an agonist for thyroid hormone receptor-beta in the pituitary gland and/or hypothalamus. Therefore, roxadustat may cause central hypothyroidism due to suppressing thyroid-stimulating hormone (TSH) release in the pituitary gland and/or thyrotropin-releasing hormone release in the hypothalamus.
View Article and Find Full Text PDFRole of imaging in the diagnosis and management of mixed epithelial and stromal tumors of the kidney: Case series and comprehensive review.
Radiol Case Rep
March 2025
Department of Radiology, University of California, Irvine, CA, USA.
Mixed epithelial and stromal tumor (MEST) of the kidney is a rare benign neoplasm composed of both stromal and epithelial components. MEST is mainly seen in adults with a strong predilection for perimenopausal women with history of hormone replacement therapy. While MEST is generally benign, there are reported cases of malignant transformation and adverse clinical outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!